Cargando…
Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome
BACKGROUND: Schistosomiasis is a neglected tropical disease burdening millions of people. One drug, praziquantel, is currently used for treatment and control. Clinically relevant drug resistance has not yet been described, but there is considerable heterogeneity in treatment outcomes, ranging from c...
Autores principales: | Schneeberger, Pierre H. H., Coulibaly, Jean T., Panic, Gordana, Daubenberger, Claudia, Gueuning, Morgan, Frey, Jürg E., Keiser, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848565/ https://www.ncbi.nlm.nih.gov/pubmed/29530088 http://dx.doi.org/10.1186/s13071-018-2739-2 |
Ejemplares similares
-
Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial
por: Coulibaly, Jean T, et al.
Publicado: (2017) -
Efficacy and Safety of Praziquantel in Preschool-Aged Children in an Area Co-Endemic for Schistosoma mansoni and S. haematobium
por: Coulibaly, Jean T., et al.
Publicado: (2012) -
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015) -
Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial
por: Barda, Beatrice, et al.
Publicado: (2016) -
Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model
por: Abla, Nada, et al.
Publicado: (2017)